While targeted therapies targeting specific driver mutations in CCA, including fibroblast growth factor receptor 2 (FGFR2) fusions and isocitrate dehydrogenase 1 (IDH1) mutations using FGFR and IDH1 inhibitors, have shown promise, these therapies only benefit a small group of CCA patients. Here, FGFR2 is linked to cholangiocarcinoma.